Previous molecular profiling of chemotherapy-resistant breast cancers has identified Ras-ERK pathway activation, degradation of ECM, AKT1 signaling via mTOR, hypoxia, EMT, and angiogenesis as activated pathways related to chemoresistance 15, 16, 18. This evidence concerns the gene MTOR and breast carcinoma.